Physician profile
Samrat Patel
NPI 1043574155
$1,596.78
in general payments reported to CMS, 2019-2025
16 companies · $74.36 in 2025
The $74.36 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $184 · 2021: $589 · 2022: $250 · 2023: $137 · 2024: $43.01 · 2025: $74.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $254.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $681.81 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $173.82 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $118.81 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $118.24 | 2019-2025 | Zerbaxa |
| Abbvie INC. | $105.46 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $92.80 | 2019-2021 | |
| Allergan, INC. | $91.76 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $48.46 | 2022-2023 | Ultomiris |
| Viatris Specialty LLC | $32.64 | 2025 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $26.92 | 2025 | Lynozyfic |
| Pfizer INC. | $21.71 | 2021 | |
| Vifor Pharma, INC. | $20.41 | 2021 | |
| Mylan Specialty L.P. | $19.09 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.13 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.54 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.18 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samrat Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.